Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.
Also called NCT07055516
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 176 participants
- Sponsor
- NodThera Ltd. (a Rezera company)
- Registry
-
NCT07055516
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT07055516. Randomized; triple masking; primary purpose treatment. Start 2025-05-08 (actual); primary completion 2026-05-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
- Acronym
- RESOLVE-1
- Condition
- Obesity and Type 2 Diabetes
- Intervention (Drug)
- NT-0796
- Intervention (Drug)
- Placebo
- Lead sponsor
- NodThera Ltd. (a Rezera company)
Record details
- Record id
cardio:ct-nct07055516- Content hash
ff306ebfa918cc1526210884417570cd52927a7a4a334e599028d02351a62b62